What is SUPN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.37B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SUPN?

P/E (TTM) is n/a and 52-week range is $37.54 to $59.68 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SUPN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SUPN?

The company profile lists revenue (TTM) near $833M, net income (TTM) near -$11.01B, EPS (TTM) near -$1.91 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Supernus Pharmaceuticals, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Rockville, Maryland, US, 58.2M shares outstanding, ISIN US8684591089 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Supernus Pharmaceuticals, Inc.

$SUPN

Health Care · Pharmaceuticals

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. The company is headquartered in Rockville, Maryland and currently employs 778 full-time employees. The company went IPO on 2010-12-28. The firm's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The firm is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

Employees

778

Website

www.supernus.com

IPO

2010-12-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US8684591089

Headquarters

Rockville, Maryland, US

Shares outstanding

58.2M

NAICS sector

Manufacturing

Institutional ownership

106.62%

Browse other companiesFree AI scores and summaries for more stocks